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Abstract
The increasing use of nanoparticles (NPs) in technological applications and in commercial 
products has escalated environmental health and safety concerns. The detection of NPs in the 
environment and in biological systems is challenged by limitations associated with commonly 
used analytical techniques. In this paper we report on the development and characterization of NP 
binding antibodies, termed NProbes. Phage display methodology was used to discover antibodies 
that bind NPs dispersed in solution. We present a proof-of-concept for the generation of NProbes 
and their use for detecting quantum dots and titanium dioxide NPs in vitro and in an ex vivo 
human skin model. Continued development and refinement of NProbes to detect NPs that vary in 
composition, shape, size, and surface coating will comprise a powerful tool kit that can be used to 
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The global total market value for nanoparticles (NPs) in biotechnology is estimated to reach 
$53.5B US dollars in 2017.1 The increased formulation of NPs in therapeutics2 and in 
consumer goods such as cosmetics,3 bicycle frames, tennis rackets, skis, and other sporting 
goods4 has raised human environmental health and safety (EH&S) concerns, especially for 
chronic low dose unintended occupational bodily exposures.5 NP safety concerns stem from 
their small size and high surface area to volume ratio, which imparts unique physiochemical 
properties and reactivity that are not present in the bulk form.6 When in contact with 
biological systems, these properties can alter tissue function7 and lead to potential 
toxicity.8, 9 While metal oxide NPs such as TiO2 and ZnO are formulated into ~70 % of all 
sunscreens10, the global market for QD NPs, which are commonly used in biomedical 
imaging,11 biosensing12 and photovoltaic13 applications, is expected to reach a value of $1.1 
billion in 2016.14
A key route for NPs to entry the body is through skin, which is the largest organ in the body. 
Existing results on NP skin penetration show varying trends that are largely dependent upon 
the NP size and surface chemistry,15–17 the skin model used,18, 19 the status of the skin 
barrier (intact or disrupted),19, 20 and the analytical techniques employed to detect the 
NPs.7, 16, 21, 22 While many studies report that for NPs to penetrate into the viable epidermis 
a defect is required in the stratum corneum barrier that maybe induced by tape stripping,19 
dermabrasion,18 flexing18, 23 or UVR exposure,20, 24 however, contrasting literature reports 
exist25, 26. It is important to note that the analytical techniques employed in these studies 
differed as would the NP detection limits which were typically not reported. For instance, it 
was observed based on TEM and tissue histology results that TiO2 and ZnO NPs 
predominantly localize as aggregates in the stratum corneum (outer most layer of skin) but 
analysis using time-of-flight secondary ion mass spectrometry (TOF-SIMS) found high 
levels of both elemental Ti and Zn deep in the epidermal layers,16 emphasizing the 
importance of considering the detection sensitivity of the analytical technique employed to 
detect NPs. Transmission electron microscopy (TEM) coupled with energy dispersive x-ray 
spectrometer (EDS) has superior nanoscale resolution and elemental detection capability 
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that can provide a detailed analysis of NP localization in sub-cellular regions; however, a 
typical tissue slice used in TEM imaging is only 70–100 nm thick.22 Therefore, NPs present 
in tissue at very low levels may be missed due to sampling error. NPs may also be missed if 
elemental levels fall below the EDS instrument detection limit. To improve on the ability to 
detect NPs using TEM a colloidal silver enhancement strategy has been developed.27 Here, 
colloidal silver selectively deposits onto metal/semiconducting NPs to produce larger 
particles that can be more easily identified and distinguished from spurious dark features. In 
previous work, we routinely observed higher QD presence in the viable epidermis using this 
procedure compared to histological analysis using fluorescence microscopy.20, 22 To achieve 
a more quantitative measure of NP presence, in vivo elemental organ analysis is typically 
performed on digested tissue samples using atomic absorption spectroscopy (AAS) or 
inductively coupled plasma mass spectrometry (ICP-MS). This approach provides a 
sensitive means to quantify the systemic transport of NPs. However, the tissue digestion 
process obfuscates the ability to distinguish transport of intact NP from soluble ion 
transport.28 For some elements detection may be masked by interference from abundant 
trace metals or from endogenous elements such as carbon.16 The isotopic enrichment 
method outlined by Gulson et al.29 can be used as a means to eliminate uncertainty 
pertaining to background levels of trace elements; however, this method is prohibitively 
expensive and impractical for routine NP studies. Confocal and fluorescence microscopy are 
also common techniques used to visualize the presence of fluorescent NPs in tissues and 
while they allow for background noise reduction, the presence of NPs at low levels may still 
be obscured by tissue autofluorescence.22
In order to unify published data on the topic of “Nanomaterials: environmental and health 
effects”, an action plan has been recommended in a recent review.30 In this plan, one of the 
recommendation states that “an integral part of the harmonization of experimental methods 
is conclusive and feasible analytics; therefore, the development of appropriate and 
inexpensive analytical methods should be a part of funding programs”.30 To this end and 
with a goal to better understand NP skin penetration, we have undertaken an effort to 
develop a simple technique that can provide information on both the NP presence and 
form 31 in the environment and in a biological milieu, which can be used in conjunction with 
existing quantitative techniques. Here we present our initial efforts to develop antibody 
reagents that bind NPs (NProbes) using phage display technology. Phage display is a 
common method used to discover protein or peptide binders to a wide variety of targets. 
Typically, the nucleotide sequence encoding a peptide is fused to the phage coat protein 
gene allowing the peptide to be displayed on the phage exterior.32 A library of phage 
displaying unique peptides is created and an affinity based selection technique (bio-panning) 
is used to discover binders. Phage display technology has been successfully used to isolate 
peptides recognizing inorganic metals 33–36, metal oxides 37–39 and semiconductors.40 In 
this work we use an antibody phage library which offers more diversity in terms of binding 
surface to discover more selective and high affinity reagents based on shape as well as 
composition. While very little is currently known about the ability of the immune system to 
recognize NPs 41, 42, NP immunogenicity is not a requirement for enrichment of antibody 
binders using in vitro display technology as we are working with a preexisting library of 
human antibodies and do not rely on an in vivo B cell immune response to occur.
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In this work NProbes were selected from a phage library consisting of ~ 2x109 unique single 
chain variable fragment (scFv) antibodies each displayed monovalently on the minor pIII 
coat protein of M13 filamentous phage. This library has been used by us previously to 
generate scFvs against proteins 43 and cell surface antigens.44 A key difference from our 
prior work is that here we have developed protocols to conduct bio-panning on NPs 
dispersed in solution rather than the standard method of immobilizing the target onto a 
substrate.45 In this work the scFv antibodies were engineered with a peptide FLAG tag 
(DYKDDDDKL) to enable secondary detection/amplification of NP presence in tissue 
sections using standard immunohistochemistry (IHC) staining with an enzymatic reporter. 
Herein, we demonstrate a proof-of-concept for NProbe generation and their use for detecting 
QDs and TiO2 NPs using in vitro assays and ex vivo human skin models.
Results and Discussion
Selection of binders to QDs and TiO2 using phage display
For NProbe discovery we used glutathione-coated (GSH) QDs (CdSe/ZnS core/shell) and 
TiO2 NPs (Evonik/Degussa, 80% anatase and 20% rutile crystal, ~21 nm primary particle 
size). We selected the GSH-QDs for their superior stability to resist agglomeration in water 
and buffer systems compared to other commonly used water soluble coatings such as 
dihydrolipoic acid (DHLA) (Supplementary Figure S1).46 The hydrodynamic diameter and 
polydispersity of the GSH-QDs measured in water using dynamic light scattering (DLS) 
were 14.1±2.5 nm and 0.33±0.06, respectively and they were negatively charged (−22.82 
mV) as determined from zeta potential measurements (pH= 5.3–5.6). The Evonik TiO2 was 
selected because of its wide use in commercial skin care products.47 TiO2 NPs dispersed in 
water form aggregates that range from ~100 nm to ~1.5 μm when visualized under TEM 
(Supplementary Figure S1). NProbes to GSH-QDs and TiO2 NPs were isolated using 
affinity-based bio-panning which involves mixing the target NPs with the phage library. The 
GSH-QDs (400 μl, 100 nM) and the TiO2 NPs (400 μl, 0.5 mg/ml) were diluted in tris-
buffered saline (TBS) and mixed with the phage library (100 μl, ~1012 phage/mL in TBS 
plus 0.5% casein) with gentle agitation. In the TBS buffer system the GSH-QDs exhibit a 
much lower tendency to agglomerate than the TiO2 as seen in TEM images (Supplementary 
Figure S1). The hydrodynamic diameter and polydispersity of the GSH-QDs in TBS was 
found to be 25.2 ±1.54 nm and 0.40 ± 0.03, respectively and they were negatively charged 
similar to the GSH-QDs in water. For GSH-QD panning the phage input library was pre-
centrifuged (Optima TLX ultracentrifuge, Beckman Coulter) at 116,000 g (65,000 rpm) to 
pellet phage agglomerates. After incubation for 2 h at room temperature, the NP/phage 
mixtures were centrifuged to pellet the NPs with bound phage. The GSH-QD/phage mixture 
was centrifuged at 83,000 g (55,000 rpm) for 10 min and the TiO2/phage mixture was 
centrifuged at 1300 g (4000 rpm) for 5 min. After removing unbound phage in the 
supernatant, the pellets were resuspended in TBS containing 0.05% Tween-20 (TBST). 
Wash cycles of centrifugation and re-suspension in TBST were repeated 5 times, following 
which the pellet was washed once in deionized water. After washing, the bound phages were 
eluted from the NPs using 0.1 M glycine (pH 2.2) and neutralized using 2 M Tris base. The 
titer of the eluted phage was quantified by transduction of ampicillin-resistant TG1 
Escherichia coli host cells and the resulting colonies were counted. A phage pool for the 
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next round of enrichment was generated by transduction of 20–100% of the previous round 
eluate. After overnight incubation, the pooled transductants were grown at 37 °C, infected 
with VCS M13 helper phage, and grown overnight at 30 °C. Phage stocks were prepared for 
the next round of panning by polyethylene glycol (PEG) precipitation. Typically, 4 rounds 
of panning were necessary to enrich for specific binders to NPs, after which a BstNI 
fingerprinting analysis was performed. The presence of identical restriction enzyme patterns 
among the tested clones was taken as evidence of specific enrichment as we have previously 
shown.44 The BstNI digests of 12 randomly selected clones following four rounds of NP 
panning typically found pattern repeats indicating 17–25% clonal abundance 
(Supplementary Figure S2). This was increased to >50% after five rounds of panning. Phage 
clones from the enriched populations, termed GSH43ϕ and Ti49ϕ, were selected for testing. 
It is important to note however, that the most abundant phage clones may not be strongest 
binders or exhibit the highest selectivity. On-going studies seek to characterize the binding 
affinity and selectivity of additional clones identified. The amino acid sequences of the 
scFvs for the two phage clones are given in Supplementary Table 1. It is interesting to point 
out that the CDR regions for both the GSH43 and the Ti49 scFvs are comprised of a high 
percentage of polar uncharged amino acids (serine and asparagine); 30% and 32%, 
respectively. Surprisingly, the CDR regions lack a preponderance of cysteines (<3%) and 
histidines (<1%) which typically are enriched in metal ion binding peptides.48 This suggests 
an alternative mechanism is important for scFv antibodies binding to NPs. The GSH43ϕ and 
Ti49ϕ phage clones and their respective purified scFv antibodies were freshly prepared and 
used for in vitro verification of target binding and cross reactivity testing to similar and 
dissimilar materials which we discuss next.
Verification of NP binding IN VITRO using phage clones
In vitro assays were conducted to quantify the binding of the GSH43ϕ and Ti49ϕ clones to 
their respective NP targets and to test their cross reactivity binding to other NPs and to 
negative control phage clones including interleukin-12 (IL-12ϕ), lactoferrin (LFϕ), human 
GRP78 (BiPϕ) and a 15 amino acid (PVSP(ps)SQKLKRKAEEDPE) peptide (Npepϕ). First, 
we used a phage centrifugation titer assay to assess binding. Here, the NPs were mixed with 
the GSH43ϕ, Ti49ϕ or IL-12ϕ clones for 2 h at room temperature. After removal of 
unbound phage by centrifugation, the pellet was washed 5 times with TBST buffer, after 
which the phages were eluted and the titers quantified as discussed above. Results for the 
GSH43ϕ and Ti49ϕ clones consistently showed a 10-fold and 100-fold increase in binding 
to their target NP, respectively relative to the IL-12ϕ negative control (Supplementary 
Figure S3). The lower enrichment value observed for the GSH43ϕ likely results from the 
precipitation of unbound phage during the ultracentrifugation step causing higher 
background counts in the colony assay despite our efforts to pre-centrifuge the phage to 
clear aggregates. These values are nonetheless are in accordance with an 8-fold enrichment 
that was reported for isolating peptides against solid ZnO substrates using phage display.38 
To show that the phage clones exhibit sequence specific binding we exchanged the light 
chain of GSH43ϕ clone with the light chain of IL-12ϕ and the hybrid phage was tested for 
binding to the GSH-QDs. This manipulation reduced the hybrid phage binding to the GSH-
QDs by a factor of 4. To further verify phage binding we conducted TEM analysis. The 
GSH-QDs were mixed separately with the GSH43ϕ clone and the IL-12ϕ negative clone. 
Ravichandran et al. Page 5













Similarly, the TiO2 NPs were mixed separately with the Ti49ϕ clone and the IL-12ϕ 
negative clone. After a 2 h incubation at room temperature the four samples were washed to 
remove unbound phages using the centrifugation procedure described above. The pellets 
were re-suspended in TBS buffer and prepared for TEM analysis. Results (Figure 1 and 
Supplementary Figure S4) show evidence for Ti49ϕ bound to TiO2 NPs (black arrows, 
Figure 1a), whereas the IL-12ϕ negative clone did not (Figure 1b). TEM results also show 
the GSH43ϕ bound to the GSH-QDs causing phage clustering (Figure 1c), whereas the 
IL-12ϕ negative phage did not (Figure 1d). The apparent association of the GSH-QD with 
the major coat protein (PVIII) is a likely artifact of the harsh ultracentrifugation process 
which may cause QDs to dislodge and become trapped in the phage pellet that is 
resuspended on the TEM grid. This does not happen in the control phage due to lack of 
GSH-QD binding in the solution phase.
To test for potential cross-reactivity binding to similar and dissimilar NPs that vary in core 
composition and surface coating we conducted phage titer assays using the centrifugation 
method and a custom plate titer assay. Results from the centrifugation titer assay (Figure 2a 
and Supplementary Figure S5) indicate that the Ti49ϕ clone binds to the TiO2 (Evonik P25) 
and to TiO2 NPs from a secondary vendor (Sigma Aldrich Inc., #677469) whereas negligible 
binding to Au-powder (<10 μm particle size Sigma Aldrich Inc., #326585), citrate coated 20 
nm Au NPs (Sigma Aldrich Inc., #753610) and carboxylated multi-walled carbon nanotubes 
(CNT-MWSusp-100, NanoLab, Inc.) is seen. Additionally, the Ti49ϕ bound other TiO2 NPs 
including TiO2-anatase crystalline form (TiO2-A, 32 nm size, Alfa Aesar) and TiO2-rutile 
crystalline form (TiO2-R, ~200 nm size, DuPont) demonstrating universal recognition of all 
forms of TiO2 NPs (Figure 2b). Highest binding was observed to TiO2-R potentially 
attributing to its larger particle sizes compared to the other forms (Supplementary Figure 
S6). The centrifugation titer assay was also used to test the cross reactivity binding of the 
GSH43ϕ clone to the carboxylated CNTs and the citrated 20 nm Au NPs which showed 
negligible binding similar to IL-12ϕ negative control (Figure 2c and Supplementary Figure 
S5).
To evaluate the cross reactivity binding of the GSH43ϕ clone to QDs with similar core 
composition (ZnS/CdSe core/shell) but different coating chemistries we developed a plate 
titer assay to minimize background signal that results from inadvertent precipitation of 
unbound phage using ultracentrifugation separation. Following a literature protocol,49 high 
binding 96 well plates were treated with 2% BSA prior to depositing the QDs. The QDs (50 
μl of a 50 nM solution in sodium bicarbonate buffer) were added to the wells and allowed to 
incubated overnight at 4 °C with gentle agitation. The deposition and adherence of QDs 
before and after the multiple washing steps (7 TBST washes, 1 water wash) was confirmed 
using a handheld UVR light source (Supplementary Figure S7). Prior to conducting cross 
reactivity studies we first validated the binding of the GSH43ϕ to immobilized GSH-QDs 
relative to empty vector phage containing the his6 and flag tags. No binding was observed 
for the empty vector phage, whereas GSH43ϕ displayed a 200-fold more binding to GSH-
QDs over phage control (Supplementary Figure S8). Moreover, the GSH43ϕ bound the 
immobilized GSH-QDs in a dose dependent manor (Supplementary Figure S8). These 
results provided confidence that the plate titer assay could be used to examine NP cross 
reactivity binding. Results from the plate titer assay (Figure 2c) show that GSH43ϕ (upon 
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elution with glycine pH 2.2) binds to GSH-QD (25.2 nm and negatively charged), Invitrogen 
QDs (Inv-QD, Invitrogen ITK™ 565-QDs, 10 nm and negatively charged), and PEI-QD (23 
nm and positively charged)46 but minimal binding to the DHLA-QD (14 nm and negatively 
charged) is observed. These data suggest that QD binding in the phage format is not specific 
to the GSH coating or to surface charge. Moreover, using the plate titer assay (Figure 2a and 
Supplementary Figure S9) we found that Ti49ϕ did not bind GSH-QDs confirming the 
absence of cross-reactivity of the Ti49ϕ clone to GSH-QDs. To confirm these results we 
next examined the scFv binding to similar and dissimilar materials which is the intended 
NProbe format.
Verification of NP binding IN VITRO using scFvs
To examine the scFv binding characteristics we generated soluble His-tagged scFv protein 
that was affinity purified and characterized by SDS-PAGE gels to verify the purity was 
>95% (Supplementary Figure S10). To examine scFv binding to similar and dissimilar 
materials we first conducted dot blot assays to test the binding of the GSH43-scFv, the Ti49-
scFv and the BiP-scFv (negative control) to GSH-QDs, Au NPs and CNTs that were spotted 
on a nitrocellulose membrane (Figure 3a(i)–3a(iii), left column). Similar to the phage 
binding studies (Figure 2c), the GSH43-scFvs showed high specific binding to the GSH-
QDs indicated by the dark chemiluminescent spot formed (Figure 3a(i), right column). 
GSH43-scFv did not bind Au NPs (pink spot, center) or CNTs (black spot, right). The 
negative control BiP-scFv (Figure 3a(ii)) and the Ti49-scFv (Figure 3a(iii)) did not bind the 
GSH-QDs, the Au NPs or the CNTs. To test the GSH43-scFv binding to similar core 
materials but with different coating ligands we spotted GSH-QDs, Inv-QDs, DHLA-QDs 
and PEI-QDs on a nitrocellulose membrane (Figure 3a(iv), left column). 
Chemiluminescence detection of scFv binding using HRP (Figure 3a(iv), right column), 
shows that GSH43-scFvs bind GSH-QDs and DHLA-QDs, but not Inv-QDs and PEI-QDs. 
The negative control NT3-scFvs (Figure 3a(v)) showed only a faint background staining to 
all these QDs. The lack of GSH43-scFv binding to the PEI-QDs is in contrast to the strong 
binding observed in the phage format (Figure 2c). We attribute this to nonspecific binding of 
the positive PEI-QDs to the M13 phages which carry a high negative surface charge.50 The 
lack of GSH43-scFv binding to the negative charged Inv-QD is also in contrast to the phage 
format results (Figure 2c). We attribute this to differences in binding affinity, as from dot 
blot concentration studies we did observe strong binding of the GSH-scFv to the Inv-QD 
with increasing GSH-scFv concentration (5–20 μg/mL) with a continued absence of binding 
to PEI-QDs (Supplementary Figure S11). The binding of GSH43-scFv to DLHA-QDs 
appears much stronger than in the plate titer assay (Figure 2c) which may suggest the QD 
coating affects adherence to BSA coated plate. Over all, these results suggest that the GSH-
scFv recognizes QDs with a similar core/shell composition but with different binding 
affinity which is also likely modulated the composition and liability of the surface ligand 
coating. Binding of GSH43-scFv to GSH-QDs was further confirmed using dynamic light 
scattering (DLS) with the BiP-scFv as the negative control. Here, the GSH-QDs were mixed 
with the scFvs at room temp for 2 h and ultra-centrifuged washed as discussed above. GSH-
QDs in TBS buffer alone were also taken through the ultra-centrifugation wash and re-
suspension steps for comparison. The hydrodynamic diameter of the GSH-QDs with bound 
GSH43-scFvs (~651 nm) was ~1.5-fold larger than that of BiP-associated GSH-QDs and 
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~2.5-fold GSH-QDs in TBS with statistical significance (Supplementary Figure S12). This 
data suggests that GSH-QDs bind to the GSH43-scFv despite their tendency to agglomerate 
in TBST. As further proof we conducted Image Stream flow cytometry measurement using 
anti-FLAG coated agarose beads. Beads coated with GSH43-scFv show intense QD 
fluorescence signal relative to beads exposed to GSH-QDs only, which showed no 
fluorescence signal. Only weak background fluorescence was detected following exposure 
of GSH-QDs to beads coated with negative control BiP-scFv (Supplementary Figure S13). 
We did not test the binding of the Ti49-scFv to TiO2 NPs by dot-blot analysis as the 
presence of the NPs on the nitrocellulose membrane could not be verified by color. Hence, 
to confirm Ti49-scFv binding we dried the TiO2 NPs onto a glass slide and used confocal 
microscopy to quantify the presence of fluorescein isothiocyanate (FITC)-conjugated anti-
FLAG reporter. Images (Figure 3b(i)) were captured under bright-field and fluorescence. A 
control slide without TiO2 NPs showed no background staining (Supplementary Figure 
S14). ImageJ (NIH) was used for analysis of line profiles of three regions of interest (ROIs) 
and the results averaged. Although a slight background signal was detected for Npep-scFv 
on TiO2 the quantification clearly shows a significant difference in the level of Ti49-scFv 
binding to TiO2 NPs compared to negative control (p<0.05, student’s unpaired t-test, Figure 
3b(ii)).
Validation of scFvs to detect NPs in a biological milieu
The main motivation for developing NProbe reagents is to facilitate the detection of NPs in 
biological systems in their particulate form. Existing studies of NP skin penetration have 
highlighted the need to consider the detection limits of the analytical techniques used as well 
as the assay protocol in drawing definitive conclusions about the NP skin penetration.16, 22 
Having developed and characterized NProbe binding reagents to TiO2 and QD NPs using in 
vitro assays, we next sought to test their ability to detect NPs in a biological milieu. First, we 
immobilized GSH-QDs on a glass slide coated with collagen, which is a key component of 
skin, and tested binding to GSH43-scFvs relative to a negative control (NPep-scFv) using 
confocal microscopy. We observed strong specific GSH43-scFvs binding to the GSH-QDs 
as indicated by the Pearson’s co-localization coefficient of 0.65 (Supplementary Figure 
S15). GSH43-scFvs did not bind collagen films without containing QDs (data not shown). 
Next, we tested the ability of the scFv to detect NPs in fresh ex vivo human skin. NPs were 
topically applied to fresh ex vivo human using established protocols.19 Following NP skin 
exposure the tissue was cryo-sectioned for immuno-histochemical (IHC) analysis using 
NProbes and a secondary anti-FLAG reporter conjugated to an alkaline phosphatase (AP). 
Skin slices were pre-treated with levamisole (5 μM) to eliminate endogenous phosphatase 
activity. Figure 4 shows bright-field and fluorescent images of a skin section following a 24 
h application GSH-QDs to the stratum corneum and a control sample (no QD exposure). The 
control sample shows negligible AP staining (Figure 4a) indicating the absence of non-
specific GSH43-scFv binding to the skin sections. In contrast, the skin sample exposed to 
GSH-QDs shows numerous punctate areas of strong AP staining in bright-field (Figure 4b). 
Observation of this skin section under fluorescence imaging shows a dense cluster of QDs 
(Figure 4c) that co-localizes with AP staining (blue arrows, Figure 4b inset). However, 
based on fluorescence imaging (Figure 4c) the detection of GSH-QD presence in skin is 
suggested to be far less than that suggested by AP staining. Using ImageJ software the 
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fluorescence image can be threshold enhanced (Figure 4d) which reveals many more 
potential instances of QDs in the skin tissue; but as previously noted22 it is difficult to 
unambiguously distinguish the QDs from tissue autofluorescence artifacts. Results from AP 
staining (Figure 4b) however, clearly demonstrate the utility of NProbes to overcome this 
challenge. The AP staining identifies many areas that co-localize with high fluorescence 
(black arrows, Figures 4b and 4d). Additionally, we observed regions with strong AP 
staining with corresponding regions that do not show presence of QD fluorescence (red 
arrows, Figures 4b and 4d). This suggests that NProbes can identify QDs whose 
fluorescence cannot be detected over background. To validate that the areas of strong AP 
staining do indeed contain QDs we used laser capture micro-dissection (LCM) microscopy 
to isolate portions of the tissue sample by catapulting them into AdhesiveCap™ microfuge 
tubes, which were then assayed for elemental cadmium (Cd) using atomic absorption 
spectroscopy (AAS). Initial studies were conducted on a skin sample with a high QD 
presence introduced by dermal injection to ensure Cd levels exceeded the AAS detection 
limit of detection (LOD) equal to 7 pg/ml. The control skin sample (no QDs) again showed 
no discernable AP staining and no visible fluorescence QD signal (exposure time: 800 ms) 
(Supplementary Figure S16). In contrast, strong AP staining is seen under bright-field in the 
dermis where GSH-QDs were injected as shown in Figure 5a with the corresponding QD 
fluorescence before dissection shown in Figure 5b. The portion of the skin marked for 
dissection is enclosed in the blue dotted area (Figure 5c). The portion remaining after 
catapult is shown in Figure 5d. AAS analysis of the tissue areas where strong QD 
fluorescence was co-localized with AP staining was performed to confirm the presence of 
Cd. Results indicated detection of 214 ng/mL of Cd.
Having demonstrated the ability of the LCM/AAS techniques to detect QD presence in the 
positive control sample, we proceeded to use this methodology to confirm the presence QDs 
in epidermal regions that exhibit strong AP staining following topical QD application on 
tape stripped skin (Supplementary Figure S17). Initial measurements of individual ROIs in 
tissue sections showed levels of Cd <LOD using AAS. However by combining six ROIs 
with strong AP staining we measured 108 pg/mL Cd, which is ~100 times above the LOD 
indicating the presence of QDs in these regions. The Cd level measured from six random 
ROI collected and combined from the control sample (no QD) was 8.5 pg/mL, which is near 
the instrument LOD (7 pg/ml) and may indicate the presence of endogenous Cd derived 
dietary sources which is more readily detected in the liver.15, 24 In addition, we collected 
and combined six ROIs with strong AP staining that lacked discernible QD signal under 
fluorescence imaging. AAS analysis measured 18 pg/mL Cd, which is above the instrument 
LOD and ~10 times higher than the endogenous Cd measured in the skin of the control (no 
QDs). These results demonstrate a proof-of-principle that NProbes can enable the detection 
of QDs (strong AP staining in bright field) present at low levels using simple IHC 
techniques.
We further sought to demonstrate the utility of NProbes by examining the penetration of 
nonfluorescent TiO2 NPs through the human skin barrier using the Ti49-scFvs. The TiO2 
NPs (Evonik) were applied to intact skin in water and we also examined a TiO2 containing 
commercial sunscreen (Eucerin SPF15). Results for both consistently show strong AP 
staining confined mainly to the upper layers of the stratum corneum (Figure 6a) relative to 
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the control (no TiO2 NPs) which did not show AP staining (Figure 6b). In some samples, we 
occasionally observed areas with mild punctate staining beneath the stratum corneum 
(Figure 6a, blue arrows) suggesting that TiO2 NPs may have penetrated the stratum corneum 
barrier. Attempts to confirm the presence of TiO2 NPs in tissue using AAS proved however, 
unsuccessful due to difficulties in dissolving TiO2 for elemental analysis and a poor AAS 
detection sensitivity for Ti ions. Therefore, we attempted to examine the epidermal regions 
exhibiting light blue staining for the presence of TiO2 particles using SEM. First, regions of 
dark staining in a control sample (TiO2 applied directly to dermis for 24 h) were analyzed to 
visualize the morphology of TiO2 NPs in the tissue milieu (Supplementary Figure S18). In 
this control tissue sample individual TiO2 NPs could be readily discerned as part of larger 
aggregates. However, SEM analysis of several experimental skin samples exhibiting light 
blue staining in the epidermis and dermis were less conclusive as individual particles in the 
TiO2 aggregates were harder to discern (Supplementary Figure S19). We were also unable 
to detect Ti ions in these regions using SEM/EDX. This is not unexpected however; as we 
estimate our TiO2 EDX detection limit to be 0.5–5 μg/cm2 which likely far exceeds the TiO2 
NP presence in these skin samples. Nevertheless, we are able to conclude that our results are 
consistent with the preponderance of recent literature investigating of TiO2 NP skin 
penetration using different animal models,17, 20, 51, 52 that significant penetration of beyond 
the stratum corneum is likely hindered by the high tendency of TiO2 NPs to agglomerate.
Conclusions
In summary, using phage display technology we have discovered and characterized for the 
first time scFv antibody reagents that bind GSH-QDs and TiO2 NPs and we have further 
demonstrated a proof-of-principle that these NProbe reagents can be used to simply detect 
NPs in skin using the standard immuno-histochemical technique. This work is unique in our 
approach to bio-pan on NPs dispersed in solution. Typically phage display requires the 
target to be immobilized onto a solid support by chemical coupling 53 or non-covalent 
adsorption to a hydrophobic surface.54 A previous study 49 reported isolation of peptides 
using phage display that bind QDs immobilized on protein (gelatin)-coated polystyrene 
plates. However, when we immobilized QDs on gelatin and performed enrichments, only 
clones that bound gelatin were found. This phenomenon has been previously reported, 
where often off-target unrelated clones are enriched that bind to other components in the 
screening system rather than the target itself.55 In fact, phage binding to components other 
than the target such as the solid phase (plastic, plates), substances used for blocking (BSA, 
milk) and capturing agents may predominate during rounds of bio-panning.55 We also 
observed this in our efforts to pan on QDs immobilized to BSA coated plate which only 
generated binders to BSA. Hence, our solution phase panning approach helps to minimize 
occurrences of false positives and favors identification of clones recognizing the NPs 
dispersed in solution. It is clear however, from the data presented that the phage are panned 
against NP aggregates and that shape must be a key recognition element as the expected 
metal binding amino acids are not predominant in the antibody CDR regions. Moreover, the 
enrichments values (10 to 100 fold) are less than expected for typical phage panning on 
proteins bound to a plate (>1000 fold). A plausible explanation is that the scFv “recognition 
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epitope” varies dynamically in the panning process due to agglomeration. Future studies are 
planned to investigate this.
In this proof-of-concept study we demonstrated the utility of scFv antibodies to detect GSH-
QDs and TiO2 NPs in both in vitro and in the ex vivo human skin model. The scFvs isolated 
did not bind dissimilar materials tested, namely Au NPs, Au powder or CNTs. Several 
controls were included to validate binding including the use of random scFvs selected from 
the library and ‘no-NP’ controls in all experiments. The data presented herein for non-
fluorescent TiO2 detection validates the preponderance of current literature, which reports 
TiO2 NPs agglomerates predominantly localize in the upper layers of the stratum corneum. 
However, we do observed instances of mild AP staining below the stratum corneum both for 
skin application of TiO2 NPs from water and from a TiO2 containing commercial sunscreen 
(Eucerin SPF 15). In these regions SEM studies confirmed the presence of structures that 
morphologically resemble TiO2 aggregates suggesting possible presence in viable skin 
layers. However, efforts to detect the elemental Ti (EDX) proved inconclusive. In the QD 
studies we were able to confirm that instances of AP straining in the epidermis with and 
without a co-localized fluorescent signal did contain elemental Cd. Hence, it is likely that 
the instances of mild AP staining in the epidermis on TiO2 treated skin (albeit less frequent 
that in QD treated skin) do indeed contain NPs. It is not unexpected that some TiO2 NPs 
could penetrate through defects in the stratum corneum barrier.
In summary, we have discovered scFv antibodies that can bind to NPs and we show the 
advantage of using enzymatic reporting to amplify the detection NPs in skin. Our 
methodology can be further exploited to develop NProbes for binding other NP types 
thereby providing an expansive tool kit that can complement other techniques to further our 
understanding of NP interactions in biological systems from a toxicology and therapeutic 
perspective. NProbes antibodies will be particularly advantageous for detecting non-
fluorescent NPs using cost-effective and common imaging techniques. Therefore, we expect 
that NProbes can be advanced and used in conjunction with conventional techniques to 
overall improve NP detection abilities in tissues and other biological systems. In future 
studies we will seek to discover the mechanisms of NP scFv binding and how binding 
affinity and selectivity relate to NP agglomeration. In addition we will construct scFv-Fc 




Commercially available CdSe/ZnS core/shell QDs capped with octadecylamine (ODA) 
(NN-Labs, 5.8 nm core diameter and 620 nm emission wavelength) were purchased. 
Previously described46 ligand exchange methods were used to prepare water-soluble GSH-
QDs. Briefly, ODA-QDs (300 μL) were precipitated by addition of methanol:acetone (1:1) 
and separated by centrifugation at 14,000 rpm for 5 min. The ODA-QDs were resuspended 
in 300 μL tetrahydrofuran (THF). 30 mg GSH (Cat. number 3541, Calbiochem) was added 
to 1 mL methanol and adjusted to pH 11.0 with tetramethylammonium hydroxide 
pentahydrate powder. The ODA-QD THF solution was slowly added to the GSH-methanol 
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solution while stirring, at room temperature in a 4 mL glass vial (VWR) immersed in a 
mineral oil bath (light white oil, Sigma-Aldrich Inc.) and the mixture was stirred at 60 °C for 
2 h on a hotplate/stirrer (VWR). The GSH-QDs were then precipitated with the addition of 
excess ether (1–2 mL) and centrifuged at 14,000 rpm for 5 min. The supernatant was 
discarded and GSH-QDs were resuspended in 300 μL 0.01 N NaOH and dialysed using a 5 
kD molecular weight cutoff DispoDialyzer filter (Harvard Apparatus Inc.) against excess 
water (50 mL water, changed once) for 48 h.
scFv Preparation
Preparation of the scFv protein from positive binders and negative controls was performed 
by removing the M13 gene III fragment of the display vector by digestion of the plasmid 
with SalI and XhoI, followed by re-ligation of the compatible ends. This manipulation also 
appends a hexa-histidine tag to the carboxy terminus of the scFv to permit affinity 
purification of the protein on an immobilized Ni2+ resin. The scFvs also contain a FLAG 
epitope (DYKDDDDKL) at the amino terminus of the light chain domain to enable 
secondary detection. After removal of gene III fragment, the scFvs were prepared by growth 
of the cultures in medium with limiting inorganic phosphate to induce expression from the 
phoA promoter. The cell pellets were lysed with BugBuster™ (Novagen) and the His-tagged 
scFvs were purified on Ni+2 magnetic beads using a Thermo KingFisher instrument to 
automate bead washing. The scFvs were eluted from the washed beads using PBS 
containing 300 mM imidazole, and stored at 4°C. Prior to using scFvs in experiments, SDS-
PAGE gel was used to confirm presence of scFvs in the sample. The gel was stained with 
Coomasie Blue (Simply Blue, Invitrogen) and photographed. The approximate concentration 
of the scFv purified was determined by measuring the absorbance at 280 nm and 
normalizing it with the reading for pure imidazole used during the above-mentioned elution 
step.
SEM Imaging
TiO2 detection limit quantification on the Zeiss Supra 40VP Field Emission SEM was done 
by preparing coverslips with 50 μL each of 1, 0.1 and 0.01 mg/mL TiO2 in water pipetted 
onto an area of 1 cm2. EDX spectra were obtained for each of the samples were a 
discernable peak for Ti was observed for 1 (50 μg/cm2 TiO2) and 0.1 mg/mL (5 μg/cm2 
TiO2) samples but not for 0.01 mg/mL (0.5 μg/cm2 TiO2) sample.
Image Stream Flow Cytometry
Anti-FLAG antibody coated commercially available beads (Sigma Aldrich Inc.) were used 
to coat GSH43 and BiP scFvs passively overnight at 4°C. Beads were collected and 
centrifuged to remove excess scFvs. The beads were blocked in 2% BSA in TBS for 1 h at 
room temperature. GSH-QDs at a concentration of 50 nM were added to samples containing 
scFv-coated beads and to a sample of uncoated beads. QDs were not added to the ‘beads 
only’ control. QDs were allowed to incubate with the beads for 2 h at room temperature with 
gentle agitation, after which the beads were washed in TBS with repeated centrifugation and 
re-suspension. The beads were finally re-suspended in 60 μL TBS and analyzed using Image 
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Stream under brightfield and fluorescence using appropriate lasers for QDs. Images were 
analyzed using IDEAS Application software (version 6.0).
Human Skin Processing and NP application
Fresh viable human skin from adult donors was obtained following a mammoplasty or 
abdominoplasty within hours of surgery. Skin samples were approved for usage by the 
University of Rochester Research Subjects Review Board (RSRB). The skin was washed 
thrice with 1X phosphate-buffered saline (PBS) and treated with fungizone (Invitrogen) to 
remove any microbial contamination. Skin was then processed to remove fat and thin the 
dermis for easy handling. The samples were placed on gauze in a sterile petri-dish filled 
with media (5–8 mL) to keep the skin viable. GSH-QDs and TiO2 NPs were applied on to 
skin in quantities lesser (0.01 mg/cm2) than those routinely used for cosmetic testing (0.05 
mg/cm2) by pipetting and spreading them evenly on the epidermal side of the skin. Skin 
samples were tape stripped (Scotch 3M 3750 clear packing tape, USA) ten times prior to 
application of GSH-QDs. Each piece of fresh tape was pressed firmly onto the epidermal 
surface of the skin and removed. GSH-QDs were also injected (50 μL in 100 μL deionized 
water) using an insulin needle (skin rested with stratum corneum facing upwards) from 
epidermis to dermis as a positive control sample. Skin samples were placed in the sterile 
hood for 24 h, after which excess NPs will be wiped off the skin surface using 1X PBS. All 
the samples were stored at −80 °C until processing for histology.
IHC
Frozen skin was mounted using TEK OCT compound, after which they were sliced (5 μm 
thickness) on to microscope slides using a cryostat (Thermo Scientific). The epidermis and 
the dermis were sectioned simultaneously to prevent accidental transfer of NPs to the blade. 
The slides were fixed in methanol (−20 °C, 10 min) prior to the experiment and dipped in 
water (Ultrapure™ water, Invitrogen) to remove excess OCT. The slides were washed twice 
with 1X TBS to wash off excess methanol and a hydrophobic pen was used to create a 
water-repellent barrier to keep reagents localized on the tissue specimen. The slides were 
blocked with normal mouse serum for 30 min at room temperature, after which GSH43-
scFvs were added to the slides diluted in BSA (10 μg/mL) and allowed to incubate overnight 
at 4 °C in a humidified chamber. The slides were washed thrice with 1X TBST and 
incubated with anti-FLAG antibody conjugated to alkaline phosphate (AP) (Sigma-Aldrich 
Inc.) for 1 h at room temperature. After washing away excess antibodies, the slides were 
incubated with BCIP/NBT (KPL) substrate for AP containing 5 mM levamisole (Vector 
laboratories Inc., CA) for 30 min at room temperature. Levamisole is an endogenous AP 
inhibitor that enables visualization of AP staining due to the binding of scFv-anti-FLAG AP-
tagged antibody alone. Excess substrate solution was washed away with DI water and 
mowiol (Fluka, #81381, Sigma Aldrich Inc., synthesized in-house) was used as a mounting 
medium for imaging. The samples were analyzed under a fluorescent microscope (Nikon 
Eclipse E800 with a Spot RTS Camera) at 40x magnification. Images were captured using 
brightfield and appropriate fluorescence filters, and analyzed using ImageJ (NIH).
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TEM studies of phage binding to respective NP. TEM images showing (a) Ti49ϕ (black 
arrows) binding TiO2 NPs whereas (b) there is no evidence for IL-12ϕ (negative control) to 
bind TiO2 NPs. Scale bar=200 nm. Inset are image enhanced to highlight the phage. (c) 
GSH43ϕ exhibit strong association and clustering with GSH-QDs whereas and (d) the 
negative control IL-12ϕ show no affinity for the GSH-QD which appear highly dispersed. 
Scale bar=50 nm.
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Figure 2a. Results from centrifugation and plate titer assays to examine Ti49ϕ phage cross 
reactivity binding to similar and dissimilar materials.
Results from the centrifugation titer assay (blue bars) indicates that Ti49ϕ binds Evonik 
TiO2 NPs (TiO2-E) and TiO2 NPs from a secondary vendor (Sigma, TiO2-S) but minimal 
binding is observed to dissimilar materials including Au-powder particles (Sigma), 20 nm 
Au (Sigma, Au20), and CNTs (NanoLab, Inc.). Using the plate titer assay theTi49ϕ bound 
the GSH-QDs at background levels. Colonies on the agar plates were counted manually and 
values plotted on the y-axis. Error bars are the (number of colonies)½. Values are 
statistically significant as observed using a Student’s t test (p<0.001).
Figure 2b. Binding of Ti49ϕ to TiO2 NPs.
Binding of Ti49ϕ to different TiO2 NPs varying in composition and source. A) Using a 
centrifugation titer assay, Ti49ϕ was found to bind TiO2-Mn (Sigma Aldrich Inc.) similar to 
TiO2 NPs (Evonik, P25), bound TiO2-R higher (by 3-fold), and bound TiO2-A by ~1.5-fold 
more than the other TiO2 NPs.
Figure 2c. Results from centrifugation and plate titer assays to examine GSH43ϕ phage 
cross reactivity binding to similar and dissimilar materials.
Plate titer assay results (red bars) indicate that the GSH43ϕ clone exhibits strong binding to 
negative charged GSH-QDs (~9-fold over the BSA-only, p=0.0035, no QD control sample), 
to negative charged Invitrogen (p=0.0005) and positive charged PEI-QDs (p=0.8, not 
significant). However, minimal binding is seen to negative charged DHLA-QDs (p=0.0028) 
and also to dissimilar materials including 20 nm Au NPs and CNTs (p=0.002) determined 
by the centrifugation titer assay (blue bars). Colonies on the agar plates were counted 
manually and values plotted on the y-axis. Error bars are the (number of colonies)½. 
Statistical analysis was done using Student’s t-test and values were considered significant if 
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p<0.05. All samples were compared to binding of GSH43ϕ to GSH-QDs to measure 
significance.
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Figure 3a: Dot blots investigating scFv binding to similar and dissimilar materials. For 
dissimilar materials, spots on a nitrocellulose membrane (left column) showing GSH-QDs 
( ), Au NPs ( ) and CNTs (black) spots. Chemiluminescence detection of scFv 
binding with HRP (right column). Results show that (i) GSH43-scFv (5 μg/mL) binds GSH-
QDs but not Au NPs and CNTs, (ii) negative control BiP-scFv (5 μg/mL) and (iii) Ti49-scFv 
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(5 μg/mL) do not bind any of the NPs. For similar materials, GSH-QDs, Invitrogen ITK™ 
565-QDs (Inv-QDs), DHLA-QDs, and PEI QDs were spotted on a nitrocellulose membrane 
(left column). Upon chemiluminescence detection of scFv binding using HRP (right 
column), results show that (iv) GSH43-scFvs bind GSH-QDs and DHLA-QDs at 5 μg/mL, 
but not Inv-QDs and PEI-QDs whereas (v) NT3 negative control scFvs show faint 
background staining at the same concentration.
Figure 3b: Brightfield and confocal images investigating the binding of Ti49-scFvs to TiO2 
NPs immobilized on a glass slide using FITC-conjugated anti-FLAG secondary antibody 
detection. (i) Representative images of negative control Npep-scFv showing minimal 
binding to TiO2 NPs (row 1), whereas Ti49-scFvs shows strong binding to TiO2 NPs (row 
2). Scale bar=20 μm. (ii) Quantitative analysis of the integrated fluorescence intensity shows 
significant difference in the Ti49-scFv treated sample compared to negative control Npep-
scFv. Data shown is average of three ROIs from the images. Error bars indicate SEM. 
**p=0.0075 using student’s unpaired t-test.
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QD detection in ex vivo human skin using GSH43-scFv. Skin slices were pretreated with 
levamisole to reduce endogenous phosphatase activity. (a) Control skin sample without 
GSH-QD exposure showing an absence of AP staining indicating a lack of GSH43-scFv 
non-specific binding to skin. (b) Brightfield image of skin sample exposed to GSH-QDs for 
24 h showing numerous areas with strong AP staining (black, , and  arrows). Inset 
shows an area of high AP staining ( ) in the epidermis that correlates with high QD 
presence as seen under (c) fluorescence imaging, exposure 1.642 s. (d) Applying a threshold 
to enhance the fluorescent signal shows that some of the areas with strong AP staining 
(black arrows) co-localize with QD fluorescence, whereas other areas ( ) indicate 
potential presence of QDs that are not visible under the fluorescence exposure conditions 
used. This suggests the ability of GSH43-scFv to detect the presence of QDs that may 
otherwise being undetectable in skin. This was confirmed with LCM studies. Scale bar=50 
μm.
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LCM imaging microscopy to confirm presence of GSH-QDs in areas of high AP staining. 
Representative skin sample containing QDs injected showing (a) dark bluish-purple staining 
indicating binding of GSH43-scFvs detected by AP. (b) Fluorescence image of skin sample 
before dissection showing QD presence. (c) Portions of stained areas were marked for cut 
and captured onto adhesive tube caps using LCM, and processed for AAS. (d) The portion 
of skin remaining after capture. Scale bar=50 μm.
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Detection of TiO2 using Ti49-scFv in human skin ex vivo. Representative images of (a) 
TiO2 applied on epidermis of intact skin,  indicates AP staining due to binding of 
Ti49-scFv to TiO2 NPs.  indicate AP staining, which could potentially be TiO2 
particles penetrated through skin to the dermis. (b) Control sample with no TiO2 applied and 
upon exposure to Ti49-scFvs, no non-specific binding (no AP staining) was observed. Scale 
bar=50 μm.
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